Key result
Prolonged dual antiplatelet therapy for three years post-stent placement was associated with 3.7% mortality, 1.48% major bleeding, and 4.4% thrombosis-restenosis.
Why the study?
Current European guidelines lack consensus on the ideal duration of dual antiplatelet therapy after coronary stent placement for myocardial infarction to prevent thrombosis-restenosis without significantly increasing bleeding risk.
Observational (n=135)
No
In a Mexican cohort of post-PPCI patients, prolonged DAPT up to 3 years was associated with a low incidence of major bleeding (1.48%) and MACE (2.2%), but a 4.4% rate of stent thrombosis-restenosis.
Suggests prolonged DAPT is well-tolerated in this specific post-PPCI population; leaves.
INTRODUCTION: In current European guidelines for the management of myocardial infarction after coronary stent placement, there is no consensus on dual antiplatelet therapy (DAPT) ideal duration to prevent stent thrombosis-restenosis without significantly increasing the bleeding risk. OBJECTIVE: To report the percentage of major bleeding and presence of major cardiovascular events associated with prolonged DAPT in patients recruited at the National Institute of Cardiology, treated with primary percutaneous coronary intervention and stent. METHODS: A longitudinal, prospective, observational, non-experimental, descriptive study was carried out. Patients were recruited from November 2016 to December 2017. RESULTS: One hundred and thirty-five patients with a mean age of 57 ± 10 years who completed the three-year follow-up were selected. Obesity and hypertension stood out as the main risk factors. After using DAPT for three years, 3.7% of mortality, 1.48% of major bleeding, and 4.4% of thrombosis-restenosis were recorded. CONCLUSIONS: Prolonged use of DAPT would be justified by the high incidence of thrombosis-restenosis, without a significant increase in bleeding risk, as well as a decrease in major cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Dámazo-Escobedo et al. (2022) conducted an observational in Myocardial infarction after coronary stent placement (n=135). Prolonged dual antiplatelet therapy (DAPT) was evaluated on Major bleeding and major cardiovascular events. Prolonged dual antiplatelet therapy for three years post-stent placement was associated with 3.7% mortality, 1.48% major bleeding, and 4.4% thrombosis-restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: